Valneva Terminates its Agreement with GSK for Regaining Control of Research and Development Assets
Shots:
- GSK to receive $10.6M as termination fees and up to $7.907M as regulatory milestone for its VLA15. Valneva to regain complete control of its R&D assets including its Lyme vaccine candidate- VLA15
- In 2007- Novartis & Intercell collaborated to accelerate vaccine for infectious diseases. Later- Intercell merged with Valneva in 2013- Novartis divested its global vaccine business (excluding influenza vaccines) to GSK in 2015
- Valneva’s VLA15 is a multivalent vaccine targeting the outer surface protein A (OspA) of Borrelia- being evaluated in P-II study and has received FDA’ s Fast Track designation. Valneva is developing VLA1553- a vaccine for chikungunya and has also received FT designation by FDA
Ref: GlobeNewsWire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com